|
|
Biomarin Pharmaceutical Inc (BMRN) |
|
Price: $87.7600
$-0.84 
-0.948%
|
| Day's High:
| $88.51
| Week Perf:
| -0.34 %
|
| Day's Low: |
$ 87.46 |
30 Day Perf: |
8.79 % |
| Volume (M): |
1,254 |
52 Wk High: |
$ 117.77 |
| Volume (M$): |
$ 110,033 |
52 Wk Avg: |
$94.58 |
| Open: |
$88.41 |
52 Wk Low: |
$76.02 |
|
|
| Market Capitalization (Millions $) |
16,777 |
| Shares
Outstanding (Millions) |
191 |
| Employees |
3,456 |
| Revenues (TTM) (Millions $) |
2,311 |
| Net Income (TTM) (Millions $) |
147 |
| Cash Flow (TTM) (Millions $) |
24 |
| Capital Exp. (TTM) (Millions $) |
107 |
Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes innovative therapies for people with rare genetic diseases. The company was founded in 1997 in California, and has since grown to become a global leader in the development of targeted therapies. BioMarin's mission is to deliver new treatments that can help people with rare diseases live longer, healthier lives.
BioMarin focuses on developing treatments for rare genetic diseases that are caused by the absence or malfunction of a single protein. These diseases often manifest in childhood and can have a devastating impact on patients and their families. In many cases, there are no approved treatments available, leaving patients with few options.
BioMarin's research and development efforts are focused on four core therapeutic areas: metabolic disorders, hemophilia, lysosomal storage disorders, and oncology. In metabolic disorders, the company is developing treatments for phenylketonuria (PKU) and achondroplasia, a form of dwarfism. In hemophilia, BioMarin is developing gene therapies that aim to cure patients of the disease. In lysosomal storage disorders, the company has developed treatments for Fabry disease and Pompe disease, and is working on treatments for mucopolysaccharidosis types I, II, and III. In oncology, BioMarin is developing a cancer immunotherapy that targets solid tumors.
BioMarin's flagship product is Palynziq, a treatment for PKU that was approved by the FDA in 2018. The company also markets Kuvan, Naglazyme, Vimizim, and Brineura, which are treatments for various rare diseases. BioMarin is committed to developing treatments that are safe and effective, and that can improve the lives of patients with rare genetic diseases.
BioMarin is headquartered in San Rafael, California, and has operations in the United States, Europe, Latin America, and Asia. The company has an experienced management team, and a strong financial position that allows it to invest in research and development. BioMarin is committed to working closely with patients, families, and advocacy groups to ensure that its treatments meet the needs of the rare disease community.
Company Address: 770 Lindaro Street San Rafael 94901 CA
Company Phone Number: 506-6700 Stock Exchange / Ticker: NASDAQ BMRN
| BMRN is expected to report next financial results on February 26, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Briacell Therapeutics Corp
The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.
|
|
Gt Biopharma Inc
The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.
|
|
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.
|
|
Procyon Corporation
Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.
|
|
China Health Industries Holdings Inc
China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.
|
| Per Share |
Current |
| Earnings (TTM) |
0.77 $ |
| Revenues (TTM) |
12.09 $
|
| Cash Flow (TTM) |
0.13 $ |
| Cash |
5.89 $
|
| Book Value |
25.62 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.77 $
|
| Revenues (TTM) |
12.09 $ |
| Cash Flow (TTM) |
0.13 $ |
| Cash |
5.89 $
|
| Book Value |
25.62 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
18.23%